Protembis announces completion of 20 cases in European CE mark study with the ProtEmbo® Cerebral Protection System


Enrollment with advanced generation device for complete cerebral protection nearing halfway mark in clinical study in Germany and Poland

Aachen, Germany, February 25, 2021

Protembis GmbH, a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of the ProtEmbo® Cerebral Protection System. The ProtEmbo® System is an intra- aortic filter device that deflects embolic material away from the brain during transcatheter aortic valve replacement (TAVR). The device is a low profile system which is delivered through the left radial artery, an ideal access site enabling physicians to avoid interference with TAVR equipment, typically delivered through the femoral artery.